Boehringer Ingelheim signs discovery deal with 4-Antibody
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is to pay the privately held Swiss company 4-Antibody up to €177.5 million as part of an agreement to discover and develop fully human therapeutic antibodies.